All In Biotech

Drug Trial Radar · NCT06392659

A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults

A Phase 1, Open-label Study Evaluating the Effect of VX-993 on the Pharmacokinetics of Midazolam, and the Effect of Itraconazole and Gemfibrozil on the Pharmacokinetics of VX-993, in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Aug 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

May 2, 2024

Primary completion

Jul 2, 2024

Study completion Jul 2, 2024

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Apr 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the pharmacokinetics (PK), drug-drug interaction, and safety and tolerability of VX-993 in healthy participants.

Conditions

  • Pain

Interventions

  • VX-993Drug

    Suspension for Oral Administration.

  • GemfibrozilDrug

    Tablets for Oral Administration.

  • ItraconazoleDrug

    Capsules for Oral Administration.

  • MidazolamDrug

    Solution for Oral Administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of Midazolam in Absence or Presence of VX-993Time frame: Pre-dose up to Day 15
  2. Part A: Maximum Observed Plasma Concentration (Cmax) of 1-Hydroxy-Midazolam in Absence or Presence of VX-993Time frame: Pre-dose up to Day 15
  3. Part A: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in Absence and Presence of VX-993Time frame: Pre-dose up to Day 15
  4. Part A: Area Under the Concentration Versus Time Curve (AUC) of 1-Hydroxy-Midazolam in Absence and Presence of VX-993Time frame: Pre-dose up to Day 15
  5. Part B: Maximum Observed Plasma Concentration (Cmax) of VX-993 in Absence or Presence of ItraconazoleTime frame: Pre-dose up to Day 27
  6. Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-993 in Absence or Presence of ItraconazoleTime frame: Pre-dose up to Day 27
  7. Part C: Maximum Observed Plasma Concentration (Cmax) of VX-993 in Absence or Presence of GemfibrozilTime frame: Pre-dose up to Day 27
  8. Part C: Area Under the Concentration Versus Time Curve (AUC) of VX-993 in Absence or Presence of GemfibrozilTime frame: Pre-dose up to Day 27

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MAC Clinical Research

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.